Navigation Links
Cancer Care Unaffected by Doctor Reimbursement Changes
Date:7/8/2008

Study says Medicare Modernization Act yet to show drop-off in access predicted by critics

TUESDAY, July 8 (HealthDay News) -- Chemotherapy patients have not lost access to care despite federal legislation that has reduced reimbursements to their doctors in recent years, a new report finds.

Critics feared the passing of the Medicare Modernization Act of 2003 would make treatment more difficult, but investigators from the Duke Clinical Research Institute (DCRI) found little difference in the distance chemo patients traveled to be treated and the time between diagnosis and start of treatment.

"The Medicare Modernization Act took issue with the fact that oncologists were often reimbursed too much -- sometimes as much as three times what they had paid -- for the chemotherapy drugs they were giving their patients, and subsequently, doctors saw those reimbursement payments fall," senior study investigator Dr. Kevin Schulman, director of the DCRI's Center for Clinical and Genetic Economics, said in a prepared statement. "The concern was that patient care would suffer if doctors had to close their practices or scale back, making it necessary for patients to travel farther or go to inpatient facilities for treatment. Our study showed that this, in fact, has not yet occurred."

The researchers studied the treatment of people with leukemia, lymphoma, breast, lung or colorectal cancer from across the United States from 2003, before the act passed, through 2006.

"The distance patients traveled for chemotherapy treatments did not considerably increase after passage of the act," lead investigator Lesley Curtis, a health services researcher in the DCRI, said in a prepared statement. "And despite concerns that patients would have to go to inpatient settings with longer wait times to be treated, we observed a small shift in the provision of initial chemotherapy from inpatient to outpatient settings between 2003 and 2006."'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Hormone Therapy Shows Little Benefit Against Prostate Cancer
2. College-Educated Fare Better When Cancer Strikes
3. FDA Approves Genetic Test for Breast Cancer
4. Thickness, Location Predict Skin Cancers Spread
5. Patients unaware of link between smoking and bladder cancer
6. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
7. Ivy Foundation Funds New Brain Cancer Research Consortium : $3M Stage I Project Aims to Improve Personalized Medicine for Patients
8. Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
9. Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer
10. Protein thought to promote cancer instead functions as a tumor suppressor
11. Overweight, insulin resistant women at greater risk of advanced breast cancer diagnosis, says study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... study by researchers from the Medical College of Wisconsin, ... for pain and other sickle cell disease complications in ... both providers and patients were also identified. The ... professor of pediatrics at the Medical College and Children,s ... be presented at the American Society of Hematology meeting ...
(Date:12/6/2009)... NEW ORLEANS, Dec. 6 Sickle cell ... red blood cells, is one of the most ... around the world, including more than 70,000 Americans.(1) ... of the American Society of Hematology highlights intriguing ... pandemic presents for children with this blood disorder, ...
(Date:12/6/2009)... A new study provides welcome news for patients with ... , The condition is estimated to impact 62,000 ... an abnormal clot forms in a vein and restricts ... some cases, the clot may detach from its point ... lungs, causing a potentially fatal condition known as a ...
(Date:12/6/2009)... Volunteer organizations and members of the community, in cooperation with the ... create a holiday party. This year,s attendance is expected to soar ... , ... (PRWEB) December 6, 2009 -- ... Greater VA Healthcare System in West Los Angeles, will once again ...
(Date:12/5/2009)... ORLEANSA new three-drug combination has shown in a phase ... effective regimen" in the treatment of patients newly diagnosed ... in bone marrow, say researchers from Dana-Farber Cancer Institute. ... of the 66 patients treated with the drug combination ... "very good partial response rate" in the phase 2 ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2
... Englishman’s love for beer and fast food, here’s some live ... on the planet, beating other European counterparts hollow.// ,A ... average life expectancy for English men is 76.6 years, ranked ... leads with an average male life expectancy of 74.8. ...
... of hospital-acquired infections from methicillin-resistant Staphylococcus aureus (MRSA), it ... major hospital trusts // in an attempt to restrict ... NHS Trust is one of the three health care ... Government scheme that would provide tips to combat the ...
... have attained the childbearing age are reported to be unsafe, according ... //In the case of Chicago, it was found to be even ... 49 years age group, at levels which exceeds the federal health ... Jack Darin has termed this as a serious problem. The mercury ...
... not taken to restrict spread of the AIDS pandemic in ... African children would be orphaned // by the end of ... 4 years time. ,The following prediction was projected ... health professionals and Government authorities from Africa, Asia, America and ...
... manufacturer of the experimental AIDS drug GS 9137 Gilead Sciences ... were successful, as lower levels of HIV were noticed in ... The experiment was conducted over a period of 10 days ... were also not seen to be of a serious nature. ...
... The American Association for Homecare announced that it disagreed ... Among them the provision to compel the transfer of ... e year and the suspension of home// health reimbursement ... on their stand, Tom Ryan, Chairman of the American ...
Other Medicine News:Health News:NHS Trust Would Soon Take On The Hospital Superbug 2Health News:The AIDS Pandemic May Orphan 18 Million African Children By 2010 2
(Date:12/4/2009)... N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: ... today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed ... Food and Drug Administration seeking approval to market its ... patent owned by Takeda Pharmaceutical Company Limited. Watson,s ...
(Date:12/4/2009)... anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder ... the comorbidities reported to occur more often in ... epilepsy versus those without an epilepsy diagnosis, according ... the U.S. ,, Findings from " CNS-Related Comorbidities ...
(Date:12/3/2009)... Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company ... for the treatment of immune mediated diseases and cancer, ... conference call on, Tuesday, December 8, 2009 at 11:00am ... to discuss clinical data regarding its HDAC Program (PCI-24781) ...
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 6418 1The Deal Names Abbott Top Dealmaker for Second Consecutive Year 6418 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 6418 3AUDIO from Medialink and Ortho McNeil Janssen Pharmaceuticals Inc 3A Getting Ready for Cold and Flu Season 6416 1Preventing H1N1 spread to health care workers 3A Dilemma debate and confusion 61746 1Preventing H1N1 spread to health care workers 3A Dilemma debate and confusion 61746 2
... Participating in Bavituximab U.S. Cancer Trial Presents ... to Anti-Angiogenesis Experts -, TUSTIN, Calif., ... PPHM ), a clinical stage biopharmaceutical,company developing ... and,hepatitis C virus infection (HCV), today reported ...
... New data showed that at 48,weeks, significantly ... to non-nucleoside reverse transcriptase inhibitors,(NNRTIs) and protease ... as less than 50 HIV-1 RNA copies/mL) ... (BR) compared with placebo plus a BR.,These ...
Other Medicine Technology:Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents 2Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents 3Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents 4New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy 2New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy 3New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy 4New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy 5New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy 6
... The Acclaim 7000 Nd:YAG laser ... by offering cosmetic procedures such as ... facial veins, our Dermique LaserFACIAL for ... offers selectable parameters for customizing treatment ...
... laser beam is delivered through an ultra thin ... the operator full freedom of movement when performing ... with a wide range of handpieces. Handpieces ... mm and 16 mm. Straight and angled ...
VERSASTEP™ Reposable Reusable Components (Standard Length)....
VERSASTEP™ Reposable Single Use Trocar For use with VERSASTEP™ Reusable Cannula, Dilator....
Medicine Products: